| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 20, 2011 | Neoprobe: Does stock’s 40% drop validate its biggest critic? | The hedge fund manager Neoprobe (NYSE Amex: NEOP) investors love to hate isn’t eager to take credit for the cancer diagnostics company’s free-falling stock price.
But the fact remains that Dublin, Ohio-based Neoprobe’s shares are down 40 pe... |
| Jun 8, 2011 | Neoprobe butts heads with Lymphoseek critics | Neoprobe Corp. (NYSE:NEOP) responded to a citizen petition sent to the U.S. Food & Drug Administration today, defending clinical trials of its Lymphoseek radiopharmaceutical.
MSMB Capital Management submitted the petition asking the FDA... |
| Neoprobe: Does stock’s 40% drop validate its biggest critic? | The hedge fund manager Neoprobe (NYSE Amex: NEOP) investors love to hate isn’t eager to take credit for the cancer diagnostics company’s free-falling stock price.
But the fact remains that Dublin, Ohio-based Neoprobe’s shares are down 40 pe... |
| Neoprobe: Hedge fund manager calls off short sale recommendation | Figuring Neoprobe‘s (NYSE Amex:NEOP) stock price has fallen far enough, the hedge fund manager who drew attention for criticizing the company has called off his recommendation to short its shares.
Martin Shkreli, CEO of New York-based hedge... |